Event Participants
Executives
5 Anand V.S. (Managing Director), Amitris (Company Secretary), Debnaran Bhattacharya (Independent Director), Jigar Kavaya (Moderator, Strategic Growth Advisors), Rishikesh Arvind Mafatlal (Chairman)
Analysts
1 Nirav Jimudia (Anvil Wealth)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue (standalone) | ₹1,372 crores (FY26) | Down ₹65 crores YoY from ₹1,437 crores; pricing pressure from Chinese dumped imports offset 3% volume growth |
| Revenue (consolidated) | ₹1,303 crores (FY26) | Down from ₹1,393 crores prior year |
| PAT (standalone) | ₹64 crores (FY26) | Down from ₹107 crores; selling price declines outpaced raw material cost benefits |
| PAT (consolidated) | ₹56 crores (FY26) | Down from ₹103 crores prior year |
| EPS (consolidated) | ₹3.84 (FY26) | Declining trend: ₹10.57 (FY22), ₹8.92 (FY23), ₹7.88 (FY24), ₹6.45 (FY25) |
| Volume growth | +3% (FY26) | H1 degrowth of 5% reversed with H2 growth of 11-12% via pricing/volume strategy and GST2 transition |
| Export revenue | ₹432 crores (FY26) | Down from ₹472 crores; impacted by US provisional tariffs and competitive pressures in key segments |
| Operating cash flow | ₹249 crores (FY26) | Strong cash generation despite profitability decline; receivables and inventories reduced |
| Freight cost | ₹38 crores (FY26) | Reduced from ₹44 crores YoY via rate optimization and per-unit cost initiatives |
| R&D spend | ~₹8 crores (FY26) | Investments in advanced products and process technologies |
| Capacity utilization | ~70% (current) | Reflects demand environment amid oversupply conditions |
| Domestic market share | ~9% (FY26) | Versus domestic market growth of 3.5%; outperformed flat global consumption trend |
| Dividend | ₹1.50/share (FY26) | Reduced from ₹2.00/share, reflecting difficult year while funding future growth |
| Q1 FY27 Revenue | ₹403 crores | Versus ₹330 crores in Q4 FY26; sequential improvement |
| Q1 FY27 PBT | ₹36 crores | Versus ₹22 crores in both March 2026 and June 2025 quarters |
Geographic & Segment Commentary
Domestic Market: Intense pressure from dumped imports and low-priced Chinese products created structural challenges. Despite this, NOCIL achieved full-year volume growth of 3% with domestic market share reaching ~9% versus market growth of 3.5%. Anti-dumping duty secured on sulfonamides (5 years from June 2026) with TDQ recommendation not accepted and PILFREX 13 decision pending by end September 2026.
Export Markets: Exports declined to ₹432 crores from ₹472 crores, impacted by higher provisional US tariffs and competitive pressures. Export volumes stagnated at 15,000-16,000 tons over the last 2-3 years, but management remains confident that China-plus-one supply chain diversification will drive medium-term growth. Customer approvals across major global accounts are steadily progressing.
Company-Specific & Strategic Commentary
Expansion Projects: TDQ expansion at Dahej commenced trial production ahead of schedule and below sanctioned budget. Board approved additional capital investment of ~₹130 crores for specialty rubber chemicals expansion along with captive intermediates. Final capacity including intermediates post-expansion will reach 135,000-140,000 tons.
Trade Remedies: Filed anti-dumping petitions on four products. DGTR recommended final findings on three (TDQ, PILFREX 13, sulfonamides); Central government approved ADD on sulfonamides only. Company continues pursuing fair trade outcomes for domestic industry competitiveness.
Cost Optimization: Focused on operational excellence, manufacturing efficiency, and asset utilization. Freight costs reduced from ₹44 crores to ₹38 crores through rate optimization and per-unit cost initiatives. Engaged consultants for productivity enhancement programs.
Balance Sheet Strength: Company remains debt-free with strong credit ratings from CARE and Crisil. Disciplined capital allocation maintained while funding growth projects.
ESG & Sustainability: Published independently assured BRSR Core Report; commitments to Responsible Care, safety, environmental stewardship, and ethical practices sustained. Green energy initiatives detailed in BRSR report.
Subsidiary Performance: Pill Chemicals Ltd (wholly-owned) recorded total income of ₹18.04 crores and PBT of ₹2.68 crores; interim dividend of ₹12.52/share declared versus ₹9.28/share prior year.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Volume growth | Double-digit growth expected over next few years | Management confident given ADD benefits, expansion projects, and China-plus-one tailwinds; export growth is prerequisite |
| ADD benefit realization | From H2 FY27 | Sulfonamide anti-dumping duty approved end June 2026 expected to support pricing and volumes |
| Capacity | 135,000-140,000 tons final capacity | Post TDQ completion and specialty chemicals expansion; includes captive intermediates |
| Q1 FY27 trajectory | Revenue ₹403 crores, PBT ₹36 crores | Significant improvement versus Q4 FY26 (revenue ₹330 crores, PBT ₹22 crores); early benefits of prior year actions visible |
| Margins | No specific guidance | Management cites high volatility and cannot commit to margin levels |
Risks & Constraints
| Risk | Context |
|---|---|
| Chinese dumping/oversupply | Continued inflow of low-priced products from China remains structural threat. However, ADD on sulfonamides approved and PILFREX 13 decision pending September 2026 provides partial mitigation; two of four ADD petitions not successful (TDQ rejected, PILFREX 13 under evaluation) |
| US tariff uncertainty | Provisional US tariffs impacted export volumes in FY26; ongoing geopolitical volatility could further pressure export economics |
| Pricing pressure | Selling prices declined materially despite volume preservation; raw material cost benefits did not offset price erosion, compressing margins and prompting dividend reduction |
| Global consumption stagnation | Global rubber consumption remained largely flat in FY26; recovery dependent on macroeconomic normalization |
| Business concentration | Rubber chemicals single-sector focus; competitors (Lanxess, Phenore, Came, China Sunshine) include China-dominant players with scale advantages |
Q&A Highlights
Volume Growth Outlook & Expansion Benefits
- Question: Given anti-dumping duty on accelerators and TDQ expansion, what volume trajectory is expected over 3-4 years and what revenue can the TDQ expansion generate? (Vinod M. Agarwal; Nirav Jimudia)
- Answer: Management expects at least double-digit volume growth over the next few years, which cannot be achieved without exports. TDQ expansion completed ahead of schedule and below budget. Export customer approvals progressing across major accounts, with China-plus-one strategy supporting growth. (Rishikesh Arvind Mafatlal)
Anti-Dumping Duty Impact
- Question: How will the ADD approval benefit NOCIL's growth and profitability over the next two years? (Amrili Larakwala)
- Answer: ADD on sulfonamides will provide some benefit in one product range, expected visible from H2 of the current year. While optimistic, management cautions that impact will be limited to the covered product category. (Rishikesh Arvind Mafatlal)
Cost Optimization & Productivity
- Question: What per-kg savings have been achieved over the last 4-5 years from input-output norm improvements and cost control initiatives? (Nirav Jimudia)
- Answer: Freight cost reduced from ₹44 crores to ₹38 crores through rate optimization and initiatives. Multiple improvement programs with consultant support underway; management declined to quantify specific savings but emphasized leaner, more productive operations. (Rishikesh Arvind Mafatlal)
EPS Declining Trend & FY27 Outlook
- Question: Since EPS has declined every year from ₹10.57 (FY22) to ₹3.84 (FY26), does FY27 reverse or decline further? (O.M. Kejriwal)
- Answer: Management acknowledged the difficult environment but highlighted Q1 FY27 improvement (PBT ₹36 crores vs ₹22 crores in both prior quarters) as evidence that the chosen direction is yielding results, though one quarter doesn't define a year. (Rishikesh Arvind Mafatlal)
Promoter Holding & Capital Raising
- Question: Are there plans to increase promoter holding (currently 23.76%) given SEBI permits up to 75%, and any rights issue/QIP plans? (Ramesh Keval Ram Channan; Bharat Raj K.)
- Answer: No plans to increase promoter holding. No rights issue or QIP indicated; expansion funded through internal accruals given debt-free status. (Rishikesh Arvind Mafatlal)
Competition & Market Share
- Question: Who are the main competitors and what is NOCIL's market share? (Sunil Modak)
- Answer: Main competitors are Lanxess, Phenore, Came, and China Sunshine (China being by far the largest). Market share reached ~9% of domestic market versus 3.5% domestic market growth, with growth higher than competitors except China. (Rishikesh Arvind Mafatlal)
R&D, AI & Innovation
- Question: What were R&D expenditures, how is AI being adopted, and what new products are in development? (Prakashini Shinoi; Bharat Raj K.; Anil Mehta)
- Answer: R&D spend was ~₹8 crores for FY26. R&D center working on advanced products and process technologies; several new products in testing expected to reach market soon. Management referenced digital technology adoption for productivity without quantifying specific AI initiatives. (Rishikesh Arvind Mafatlal)
Key Takeaway
NOCIL delivered a resilient FY26 amid severe Chinese dumping pressures, reporting ₹1,372 crores standalone revenue (down from ₹1,437 crores) and PAT of ₹64 crores (down from ₹107 crores), while achieving 3% volume growth that reversed an H1 contraction on the back of 11-12% H2 growth. The company secured anti-dumping duty on sulfonamides (5-year term) with PILFREX 13 pending September 2026, completed TDQ expansion at Dahej ahead of schedule, and approved ₹130 crores for specialty chemicals expansion targeting 135,000-140,000 tons final capacity. Q1 FY27 showed encouraging recovery with revenue of ₹403 crores and PBT of ₹36 crores, nearly double prior quarters. Strategy centers on China-plus-one opportunities, cost optimization (freight down from ₹44 to ₹38 crores), and export customer approvals, with management guiding toward double-digit volume growth over the next few years. Key watch points include potential ADD rejections, US tariff trajectory, and margin recovery durability amid continued oversupply.